Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biogen Inc. stock logo
BIIB
Biogen
$130.71
-0.5%
$141.40
$128.51
$238.00
$19.13B0.011.31 million shs1.76 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$788.62
-3.6%
$849.30
$711.40
$972.53
$747.75B0.343.31 million shs2.67 million shs
Roche Holding AG stock logo
RHHBY
Roche
$40.02
+1.7%
$41.41
$29.20
$44.31
$255.24B0.413.23 million shs3.87 million shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biogen Inc. stock logo
BIIB
Biogen
-0.54%-7.80%-7.33%-12.45%-36.76%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
+1.97%-0.88%-11.90%+5.33%+7.28%
Roche Holding AG stock logo
RHHBY
Roche
-4.16%-7.65%-5.88%+12.68%+25.46%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Biogen Inc. stock logo
BIIB
Biogen
4.9038 of 5 stars
4.25.00.03.73.42.51.9
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
4.8108 of 5 stars
2.45.03.34.03.32.51.9
Roche Holding AG stock logo
RHHBY
Roche
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Biogen Inc. stock logo
BIIB
Biogen
2.43
Hold$213.3363.21% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.84
Moderate Buy$1,009.7228.04% Upside
Roche Holding AG stock logo
RHHBY
Roche
2.50
Moderate BuyN/AN/A

Current Analyst Ratings Breakdown

Latest LLY, BIIB, and RHHBY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/6/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$1,146.00
3/5/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$970.00 ➝ $1,100.00
2/18/2025
Biogen Inc. stock logo
BIIB
Biogen
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$138.00 ➝ $135.00
2/13/2025
Biogen Inc. stock logo
BIIB
Biogen
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Outperform ➝ Sector Outperform$244.00 ➝ $224.00
2/13/2025
Biogen Inc. stock logo
BIIB
Biogen
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Perform ➝ Market Perform$156.00 ➝ $139.00
2/13/2025
Biogen Inc. stock logo
BIIB
Biogen
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$281.00 ➝ $245.00
2/13/2025
Biogen Inc. stock logo
BIIB
Biogen
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$192.00 ➝ $157.00
2/13/2025
Biogen Inc. stock logo
BIIB
Biogen
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$160.00 ➝ $145.00
2/13/2025
Biogen Inc. stock logo
BIIB
Biogen
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$231.00 ➝ $225.00
2/13/2025
Biogen Inc. stock logo
BIIB
Biogen
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$165.00 ➝ $140.00
2/13/2025
Biogen Inc. stock logo
BIIB
Biogen
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$220.00 ➝ $210.00
(Data available from 4/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Biogen Inc. stock logo
BIIB
Biogen
$9.68B1.98$21.46 per share6.09$114.71 per share1.14
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$45.04B16.60$12.86 per share61.34$15.05 per share52.40
Roche Holding AG stock logo
RHHBY
Roche
$68.73B3.71$3.12 per share12.82$5.81 per share6.89
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Biogen Inc. stock logo
BIIB
Biogen
$1.63B$11.1911.687.921.5116.87%14.98%8.76%4/23/2025 (Estimated)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$10.59B$11.7167.3525.341.4023.51%85.24%16.19%5/1/2025 (Estimated)
Roche Holding AG stock logo
RHHBY
Roche
$9.40BN/A0.0013.342.18N/AN/AN/AN/A

Latest LLY, BIIB, and RHHBY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2025N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$4.64N/AN/AN/A$12.77 billionN/A
4/23/2025N/A
Biogen Inc. stock logo
BIIB
Biogen
$3.59N/AN/AN/A$2.25 billionN/A
2/12/2025Q4 2024
Biogen Inc. stock logo
BIIB
Biogen
$3.43$3.44+$0.01$1.83$2.42 billionN/A
2/6/2025Q4 2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.45$5.32-$0.13$4.88$13.42 billionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Biogen Inc. stock logo
BIIB
Biogen
N/AN/AN/AN/AN/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.000.76%+15.21%51.24%11 Years
Roche Holding AG stock logo
RHHBY
Roche
$0.852.12%N/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Biogen Inc. stock logo
BIIB
Biogen
0.27
1.35
0.90
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.00
1.15
0.97
Roche Holding AG stock logo
RHHBY
Roche
0.86
1.26
0.97

Institutional Ownership

CompanyInstitutional Ownership
Biogen Inc. stock logo
BIIB
Biogen
87.93%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Roche Holding AG stock logo
RHHBY
Roche
N/A

Insider Ownership

CompanyInsider Ownership
Biogen Inc. stock logo
BIIB
Biogen
0.16%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.13%
Roche Holding AG stock logo
RHHBY
Roche
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Biogen Inc. stock logo
BIIB
Biogen
8,720146.38 million146.14 millionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
39,000948.17 million948.08 millionOptionable
Roche Holding AG stock logo
RHHBY
Roche
103,6056.38 billionN/ANot Optionable

Recent News About These Companies

Roche’s Genentech present data on trontinemab, Elecsys plasma test
EMA put clinical hold on Roche, Sarepta DMD studies after death
Roche stock falls following Ocrevus trial update
Roche says MUSETTE trial did not meet primary endpoint

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Biogen stock logo

Biogen NASDAQ:BIIB

$130.71 -0.61 (-0.46%)
Closing price 04:00 PM Eastern
Extended Trading
$130.49 -0.22 (-0.17%)
As of 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$788.62 -29.60 (-3.62%)
Closing price 03:59 PM Eastern
Extended Trading
$787.38 -1.24 (-0.16%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Roche stock logo

Roche OTCMKTS:RHHBY

$40.02 +0.65 (+1.65%)
As of 03:59 PM Eastern

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.